These results suggest that multiple signalling pathways may be cooperating in preserving telomeres of ALT cells and that deregulating ALT activity by ponatinib-based combinatorial treatments may represent one compelling therapeutic option for ALT cancers (Fig. 8). This evidence concerns the gene GPT and cancer.